Aveo Pharmaceuticals (AVEO)
NASDAQ:AVEO

AVEO Pharma (AVEO) Income Statement

1,352 Followers

AVEO Pharma Income Statement

Last quarter (Q3 2022), AVEO Pharma's total revenue was $30.45M, an increase of 100.68% from the same quarter last year. In Q3, AVEO Pharma's net income was $-3.27M. See AVEO Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 94.32M$ 42.30M$ 6.02M$ 28.80M$ 5.41M$ 7.58M
Cost of Revenue
$ 11.50M$ 4.74M$ 0.00---
Gross Profit
$ 82.82M$ 37.56M$ 6.02M---
Operating Expense
$ 107.32M$ 87.11M$ 44.90M$ 29.17M$ 31.43M$ 34.32M
Operating Income
$ -24.49M$ -49.55M$ -38.88M$ -374.00K$ -26.02M$ -26.74M
Net Non Operating Interest Income Expense
$ -4.60M$ -4.04M$ -1.60M$ -1.81M$ -2.19M$ -2.37M
Other Income Expense
$ 58.00K$ 257.00K$ 4.90M$ 11.58M$ 22.89M$ -35.81M
Pretax Income
$ -29.04M$ -53.34M$ -35.58M$ 9.39M$ -5.33M$ -64.92M
Tax Provision
--$ 0.00$ 0.00$ 0.00$ 101.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -29.04M$ -53.34M$ -35.58M$ 9.39M$ -5.33M$ -65.03M
Basic EPS
$ -0.84$ -1.63$ -1.66$ 0.61$ -0.44$ -6.14
Diluted EPS
$ -0.84$ -1.63$ -1.66$ 0.61$ -1.93$ -6.14
Basic Average Shares
$ 138.00M$ 32.66M$ 21.40M$ 15.33M$ 12.06M$ 10.59M
Diluted Average Shares
$ 138.00M$ 32.66M$ 21.40M$ 15.38M$ 13.07M$ 10.59M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 118.81M$ 91.85M$ 44.90M$ 29.17M$ 31.43M$ 34.32M
Net Income From Continuing And Discontinued Operation
$ -29.04M$ -53.34M$ -35.58M$ 9.39M$ -5.33M$ -65.03M
Normalized Income
$ -29.04M$ -53.54M$ -40.48M$ -2.19M$ -25.25M$ -44.78M
Interest Expense
$ 4.60M$ 4.04M$ 1.60M$ 1.81M$ 2.19M$ 2.37M
EBIT
$ -24.43M$ -49.30M$ -33.98M$ 11.20M$ -3.14M$ -62.55M
EBITDA
$ -24.37M$ -49.23M$ -33.96M$ 11.20M$ -3.14M$ -62.55M
Currency in USD

AVEO Pharma Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis